Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
REDWOOD CITY, Calif., May 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2017 financial results after market close on Tuesday, May 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 14067412 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 14067412 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS:
Investors
LHA
Jody Cain, 310 691 7100
[email protected]
